Development of novel quinazoline based ATR inhibitors: Implications for DNA damage response in ATM-deficient and ATM-proficient cancer cells

Key Points

• Quinazoline-based ATR inhibitors effectively target DNA damage response in cancer cells.
• In ATM-deficient cancer cells, these inhibitors significantly enhance the therapeutic impact.
• Research involved developing novel compounds and analyzing their effects on DNA repair mechanisms.
• Targeting ATR could offer new avenues for cancer treatment, especially in specific patient populations.